You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameImatinib
Accession NumberDB00619  (APRD01028, EXPT02967, DB03261)
TypeSmall Molecule
GroupsApproved
DescriptionImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Structure
Thumb
Synonyms
4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
Imatinib
Imatinib Methansulfonate
Imatinibum
STI 571
External Identifiers
  • CGP-57148B
  • STI-571
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Imatinibtablet100 mgoralActavis Pharma Company2014-04-29Not applicableCanada
Act Imatinibtablet400 mgoralActavis Pharma Company2014-04-29Not applicableCanada
Gleevectablet100 mg/1oralNovartis Pharmaceuticals Corporation2001-05-15Not applicableUs
Gleevectablet100 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Gleevectablet400 mg/1oralNovartis Pharmaceuticals Corporation2001-05-15Not applicableUs
Gleevectablet100 mgoralNovartis Pharmaceuticals Canada Inc2005-04-05Not applicableCanada
Gleevectablet400 mg/1oralNovartis Pharmaceuticals Corporation2014-12-23Not applicableUs
Gleeveccapsule100 mgoralNovartis Pharmaceuticals Canada Inc2001-09-262008-09-24Canada
Gleevectablet400 mgoralNovartis Pharmaceuticals Canada Inc2004-10-25Not applicableCanada
Gleevectablet100 mg/1oralNovartis Pharma Produktions Gmb H2001-05-15Not applicableUs
Mylan-imatinibtablet400 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-imatinibtablet100 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-imatinibtablet100 mgoralPharmascience Inc2015-05-26Not applicableCanada
PMS-imatinibtablet400 mgoralPharmascience Inc2015-05-26Not applicableCanada
Ran-imatinibtablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-imatinibtablet400 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Teva-imatinibtablet100 mgoralTeva Canada Limited2013-04-02Not applicableCanada
Teva-imatinibtablet400 mgoralTeva Canada Limited2013-05-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imatinibtablet100 mgoralApotex Inc2013-04-19Not applicableCanada
Apo-imatinibtablet400 mgoralApotex Inc2013-04-19Not applicableCanada
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet100 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib AccordFilm-coated tablet400 mgOral useAccord Healthcare Ltd2013-07-01Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard50 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard100 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisFilm-coated tablet400 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib ActavisCapsule, hard50 mgOral useActavis Group Ptc Ehf2013-04-17Not applicableEu
Imatinib MedacCapsule, hard400 mgOral useMedac2013-09-25Not applicableEu
Imatinib MedacCapsule, hard100 mgOral useMedac2013-09-25Not applicableEu
Imatinib Mesylatetablet, film coated100 mg/1oralAmerican Health Packaging2016-02-15Not applicableUs
Imatinib Mesylatetablet, film coated400 mg/1oralAmerican Health Packaging2016-02-15Not applicableUs
Imatinib Mesylatetablet, film coated100 mg/1oralSun Pharma Global FZE2016-02-01Not applicableUs
Imatinib Mesylatetablet, film coated400 mg/1oralSun Pharma Global FZE2016-02-01Not applicableUs
Imatinib TevaCapsule, hard100 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet400 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard400 mgTeva B.V.2013-01-08Not applicableEu
Imatinib TevaCapsule, hard100 mgOral useTeva B.V.2013-01-08Not applicableEu
Imatinib TevaFilm-coated tablet100 mgOral useTeva B.V.2013-01-08Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CelonibCelon
EnlivenOrion
GlivecNovartis
ImatibGrey Inversiones
MesylonibMiracalus
MitinabGlenmark
PlivatinibPliva
ShantinibShantha
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Imatinib Mesylate
Thumb
  • InChI Key: YLMAHDNUQAMNNX-UHFFFAOYSA-N
  • Monoisotopic Mass: 589.247123333
  • Average Mass: 589.708
DBSALT000098
Categories
UNIIBKJ8M8G5HI
CAS number152459-95-5
WeightAverage: 493.6027
Monoisotopic: 493.259008649
Chemical FormulaC29H31N7O
InChI KeyInChIKey=KTUFNOKKBVMGRW-UHFFFAOYSA-N
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
IUPAC Name
N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
SMILES
CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • Pyridinylpyrimidine
  • N-arylamide
  • Diaminotoluene
  • Benzoic acid or derivatives
  • Aminotoluene
  • Phenylmethylamine
  • Benzylamine
  • Benzoyl
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Toluene
  • Pyrimidine
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
PharmacodynamicsImatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.
Mechanism of actionImatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) - called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib.
Related Articles
AbsorptionThe pharmacokinetics in CML and GIST patients are similar. Imatinib is well absorbed with mean absolute bioavailability is 98% and maximum plasma levels achieved within 2-4 hours of dosing
Volume of distributionNot Available
Protein binding95% protein bound, mostly to albumin and alpha-1-acid glycoprotein.
Metabolism

Primarily hepatic via CYP3A4. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. This metabolite is similar in potency to the parent compound.

SubstrateEnzymesProduct
Imatinib
N-desmethylimatinib (CGP74588)Details
Imatinib
AFN911Details
Imatinib
CGP71422Details
Imatinib
CGP72383Details
Imatinib
Not Available
n-demethylated piperazineDetails
Route of eliminationImatinib elimination is predominately in the feces, mostly as metabolites. 81% of the dose is eliminated within 7 days, in feces (68% of the dose) and urine (13% of the dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faces), the remainder being metabolites.
Half lifeFollowing oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.
Clearance
  • 8 L/h [50-year-old CML and GIST patient weighing 50 kg]
  • 14 L/h [50-year-old CML and GIST patient weighing 100 kg]
ToxicityThe most frequently reported adverse reactions (>30%) were edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.7624
Caco-2 permeable+0.5076
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8107
P-glycoprotein inhibitor IINon-inhibitor0.5326
Renal organic cation transporterInhibitor0.5299
CYP450 2C9 substrateNon-substrate0.8287
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6547
CYP450 1A2 substrateNon-inhibitor0.6602
CYP450 2C9 inhibitorNon-inhibitor0.8813
CYP450 2D6 inhibitorNon-inhibitor0.7933
CYP450 2C19 inhibitorNon-inhibitor0.8516
CYP450 3A4 inhibitorNon-inhibitor0.9313
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7962
Ames testNon AMES toxic0.8134
CarcinogenicityNon-carcinogens0.919
BiodegradationNot ready biodegradable0.9819
Rat acute toxicity2.6013 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7709
hERG inhibition (predictor II)Inhibitor0.8887
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg
Tabletoral100 mg/1
Tabletoral100 mg
Tabletoral400 mg
Tabletoral400 mg/1
Film-coated tabletOral use100 mg
Film-coated tabletOral use400 mg
Capsule, hardOral use100 mg
Capsule, hardOral use400 mg
Capsule, hardOral use50 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral400 mg/1
Capsule, hard400 mg
Capsule, hard100 mg
Capsule, hard400 mg
Prices
Unit descriptionCostUnit
Gleevec 400 mg tablet174.38USD tablet
Gleevec 100 mg tablet41.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2093203 No2002-11-262013-04-01Canada
US5521184 Yes1995-07-042015-07-04Us
US6894051 Yes1999-11-232019-11-23Us
US6958335 Yes2002-06-192022-06-19Us
US7544799 Yes1999-01-162019-01-16Us
USRE43932 Yes1999-01-162019-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226 °C (mesylate salt)Not Available
water solubilityVery soluble in water at pH < 5.5 (mesylate salt)Not Available
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0146 mg/mLALOGPS
logP3.47ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)8.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.28 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity148.93 m3·mol-1ChemAxon
Polarizability55.54 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5521184
General References
  1. Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003 Sep;55(3):401-23. Epub 2003 Jul 17. [PubMed:12869662 ]
  2. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001 Feb;7(2):228-34. [PubMed:11175855 ]
  3. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. [PubMed:16779792 ]
  4. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 May;24(5):935-42. Epub 2004 Feb 26. [PubMed:14988091 ]
  5. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med. 2005 Jul;11(7):731-9. Epub 2005 Jun 26. [PubMed:15980865 ]
External Links
ATC CodesL01XE01
AHFS Codes
  • 10:00.00
  • 92:00.00
PDB Entries
FDA labelDownload (129 KB)
MSDSDownload (217 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Imatinib can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Imatinib.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Imatinib.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Imatinib.
AcetaminophenAcetaminophen may increase the hepatotoxic activities of Imatinib.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Imatinib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Imatinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Imatinib.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Imatinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Imatinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Imatinib.
AlbendazoleThe serum concentration of Imatinib can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Imatinib.
AldosteroneThe serum concentration of Imatinib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Imatinib.
AlectinibThe serum concentration of Imatinib can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Imatinib.
AlfentanilThe serum concentration of Imatinib can be increased when it is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Imatinib.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Imatinib.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Imatinib.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Imatinib.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Imatinib.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Imatinib.
AlosetronThe metabolism of Alosetron can be decreased when combined with Imatinib.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Imatinib.
AmantadineThe serum concentration of Imatinib can be increased when it is combined with Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Imatinib.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Imatinib.
Aminohippuric acidThe serum concentration of Imatinib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Imatinib.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Imatinib.
AmiodaroneThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Imatinib.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Imatinib.
AmitriptylineThe serum concentration of Imatinib can be increased when it is combined with Amitriptyline.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Imatinib.
AmlodipineThe serum concentration of Imatinib can be increased when it is combined with Amlodipine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Imatinib.
AmprenavirThe serum concentration of Imatinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Imatinib can be increased when it is combined with Amsacrine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Imatinib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Imatinib.
ApremilastThe metabolism of Apremilast can be decreased when combined with Imatinib.
AprepitantThe serum concentration of Imatinib can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Imatinib.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Imatinib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.
ArmodafinilThe metabolism of Imatinib can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Imatinib.
ArtemetherThe metabolism of Artemether can be decreased when combined with Imatinib.
AsenapineThe metabolism of Asenapine can be decreased when combined with Imatinib.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Imatinib.
AstemizoleThe serum concentration of Imatinib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Imatinib can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Imatinib.
AtenololThe serum concentration of Imatinib can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Imatinib can be increased when it is combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Imatinib.
AtorvastatinThe serum concentration of Imatinib can be increased when it is combined with Atorvastatin.
AvanafilThe metabolism of Avanafil can be decreased when combined with Imatinib.
AxitinibThe metabolism of Axitinib can be decreased when combined with Imatinib.
AzelastineThe metabolism of Azelastine can be decreased when combined with Imatinib.
AzelastineThe serum concentration of Imatinib can be increased when it is combined with Azelastine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Imatinib.
AzithromycinThe serum concentration of Imatinib can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Imatinib.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Imatinib.
BenzocaineThe serum concentration of Imatinib can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Imatinib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Imatinib.
BepridilThe serum concentration of Imatinib can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Imatinib.
BetaxololThe metabolism of Imatinib can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Imatinib.
BexaroteneThe serum concentration of Imatinib can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Imatinib.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Imatinib.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Imatinib.
BiperidenThe serum concentration of Imatinib can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Imatinib.
BoceprevirThe serum concentration of Imatinib can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Imatinib.
BortezomibThe serum concentration of Imatinib can be increased when it is combined with Bortezomib.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Imatinib.
BosentanThe serum concentration of Imatinib can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Imatinib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Imatinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Imatinib.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Imatinib.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Imatinib.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Imatinib.
BromocriptineThe serum concentration of Imatinib can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Imatinib.
BudesonideThe metabolism of Budesonide can be decreased when combined with Imatinib.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Imatinib.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Imatinib.
BuprenorphineThe serum concentration of Imatinib can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Imatinib.
BuspironeThe metabolism of Buspirone can be decreased when combined with Imatinib.
BuspironeThe serum concentration of Imatinib can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Imatinib.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Imatinib.
CabazitaxelThe serum concentration of Imatinib can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Imatinib.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Imatinib.
CaffeineThe metabolism of Caffeine can be decreased when combined with Imatinib.
CaffeineThe serum concentration of Imatinib can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Imatinib.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Imatinib.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Imatinib.
CanagliflozinThe serum concentration of Imatinib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Imatinib can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Imatinib can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Imatinib can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Imatinib.
CarbamazepineThe serum concentration of Imatinib can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Imatinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Imatinib.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Imatinib.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Imatinib.
CarvedilolThe serum concentration of Imatinib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Imatinib can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Imatinib.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Imatinib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Imatinib.
CeritinibThe serum concentration of Imatinib can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Imatinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Imatinib.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Imatinib.
ChloramphenicolThe metabolism of Imatinib can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Imatinib.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Imatinib.
ChloroquineThe serum concentration of Imatinib can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Imatinib.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Imatinib.
ChlorpromazineThe serum concentration of Imatinib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Imatinib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Imatinib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Imatinib.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Imatinib.
CholesterolThe serum concentration of Imatinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Imatinib can be decreased when it is combined with Cholic Acid.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Imatinib.
CilazaprilThe serum concentration of Imatinib can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Imatinib.
CimetidineThe serum concentration of Imatinib can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Imatinib.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Imatinib.
CiprofloxacinThe serum concentration of Imatinib can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Imatinib.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Imatinib.
CitalopramThe metabolism of Citalopram can be decreased when combined with Imatinib.
CitalopramThe serum concentration of Imatinib can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Imatinib can be increased when it is combined with Clarithromycin.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Imatinib.
ClemastineThe serum concentration of Imatinib can be increased when it is combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Imatinib.
ClobazamThe metabolism of Clobazam can be decreased when combined with Imatinib.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Imatinib.
ClofazimineThe serum concentration of Imatinib can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Imatinib.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Imatinib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Imatinib.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Imatinib.
ClomipramineThe serum concentration of Imatinib can be increased when it is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Imatinib.
ClonidineThe metabolism of Clonidine can be decreased when combined with Imatinib.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Imatinib.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Imatinib.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Imatinib.
ClotrimazoleThe serum concentration of Imatinib can be increased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Imatinib is combined with Clozapine.
ClozapineThe metabolism of Imatinib can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Imatinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Imatinib.
CocaineThe metabolism of Cocaine can be decreased when combined with Imatinib.
CodeineThe metabolism of Codeine can be decreased when combined with Imatinib.
ColchicineThe metabolism of Colchicine can be decreased when combined with Imatinib.
ColchicineThe serum concentration of Imatinib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Imatinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Imatinib can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Imatinib.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Imatinib.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Imatinib.
CrizotinibThe serum concentration of Imatinib can be increased when it is combined with Crizotinib.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Imatinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Imatinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Imatinib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.
Cyproterone acetateThe serum concentration of Imatinib can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Imatinib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Imatinib.
DabrafenibThe serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Imatinib.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Imatinib.
DaclatasvirThe serum concentration of Imatinib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Imatinib can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Imatinib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Imatinib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Imatinib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Imatinib.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Imatinib.
DarunavirThe serum concentration of Imatinib can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Imatinib.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Imatinib.
DasatinibThe serum concentration of Imatinib can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Imatinib.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Imatinib.
DaunorubicinThe serum concentration of Imatinib can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Imatinib.
DeferasiroxThe serum concentration of Imatinib can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Imatinib.
DelavirdineThe serum concentration of Imatinib can be increased when it is combined with Delavirdine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Imatinib.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Imatinib.
DesipramineThe serum concentration of Imatinib can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Imatinib.
DesloratadineThe serum concentration of Imatinib can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.
DexamethasoneThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Imatinib.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Imatinib.
DextromethorphanThe serum concentration of Imatinib can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Imatinib.
DiazepamThe metabolism of Diazepam can be decreased when combined with Imatinib.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Imatinib.
DiclofenacThe serum concentration of Imatinib can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imatinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Imatinib.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Imatinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Imatinib.
DigoxinThe metabolism of Digoxin can be decreased when combined with Imatinib.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Imatinib.
DihydroergotamineThe serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Imatinib.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Imatinib.
DiltiazemThe serum concentration of Imatinib can be increased when it is combined with Diltiazem.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Imatinib.
DiphenhydramineThe metabolism of Imatinib can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Imatinib can be increased when it is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Imatinib.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Imatinib.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Imatinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Imatinib.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Imatinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Imatinib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Imatinib.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Imatinib.
DoxazosinThe serum concentration of Imatinib can be increased when it is combined with Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Imatinib.
DoxepinThe serum concentration of Imatinib can be increased when it is combined with Doxepin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Imatinib.
DoxorubicinThe serum concentration of Imatinib can be decreased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Imatinib can be increased when it is combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Imatinib.
DronedaroneThe serum concentration of Imatinib can be increased when it is combined with Dronedarone.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Imatinib.
DuloxetineThe metabolism of Imatinib can be decreased when combined with Duloxetine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Imatinib.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Imatinib.
EfavirenzThe serum concentration of Imatinib can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Imatinib.
ElbasvirThe serum concentration of Imatinib can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Imatinib.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Imatinib.
EltrombopagThe serum concentration of Imatinib can be increased when it is combined with Eltrombopag.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Imatinib.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Imatinib.
EnalaprilThe serum concentration of Imatinib can be increased when it is combined with Enalapril.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Imatinib.
EnzalutamideThe serum concentration of Imatinib can be increased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Imatinib.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Imatinib.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Imatinib.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Imatinib.
ErgonovineThe serum concentration of Imatinib can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Imatinib.
ErgotamineThe serum concentration of Imatinib can be increased when it is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Imatinib.
ErythromycinThe serum concentration of Imatinib can be increased when it is combined with Erythromycin.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Imatinib.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Imatinib.
Eslicarbazepine acetateThe serum concentration of Imatinib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Imatinib.
EstazolamThe metabolism of Estazolam can be decreased when combined with Imatinib.
EstradiolThe metabolism of Estradiol can be decreased when combined with Imatinib.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Imatinib.
EstramustineThe metabolism of Estramustine can be decreased when combined with Imatinib.
EstramustineThe serum concentration of Imatinib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Imatinib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Imatinib.
EstroneThe metabolism of Estrone can be decreased when combined with Imatinib.
EstroneThe serum concentration of Imatinib can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Imatinib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Imatinib.
EthanolThe metabolism of Ethanol can be decreased when combined with Imatinib.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Imatinib.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Imatinib.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Imatinib.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Imatinib.
EtoposideThe metabolism of Etoposide can be decreased when combined with Imatinib.
EtoposideThe serum concentration of Imatinib can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Imatinib.
EtravirineThe serum concentration of Imatinib can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Imatinib.
EverolimusThe metabolism of Everolimus can be decreased when combined with Imatinib.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Imatinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Imatinib.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Imatinib.
FelbamateThe metabolism of Felbamate can be decreased when combined with Imatinib.
FelodipineThe metabolism of Felodipine can be decreased when combined with Imatinib.
FelodipineThe serum concentration of Imatinib can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Imatinib.
FentanylThe metabolism of Fentanyl can be decreased when combined with Imatinib.
FentanylThe serum concentration of Imatinib can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.
FexofenadineThe serum concentration of Imatinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Imatinib.
FinasterideThe metabolism of Finasteride can be decreased when combined with Imatinib.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Imatinib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Imatinib.
FloxuridineThe metabolism of Imatinib can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Imatinib can be increased when it is combined with Fluconazole.
FludarabineImatinib may decrease the myelosuppressive activities of Fludarabine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Imatinib.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Imatinib.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Imatinib.
FluorouracilThe metabolism of Imatinib can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Imatinib.
FluoxetineThe serum concentration of Imatinib can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Imatinib can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Imatinib can be increased when it is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Imatinib.
FlurazepamThe serum concentration of Imatinib can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Imatinib.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Imatinib.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Imatinib.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Imatinib.
FluvoxamineThe serum concentration of Imatinib can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Imatinib can be increased when it is combined with Fosamprenavir.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Imatinib.
FosaprepitantThe serum concentration of Imatinib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Imatinib can be decreased when it is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Imatinib.
Fusidic AcidThe serum concentration of Imatinib can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Imatinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Imatinib.
GefitinibThe serum concentration of Imatinib can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Imatinib.
GemfibrozilThe serum concentration of the active metabolites of Imatinib can be reduced when Imatinib is used in combination with Gemfibrozil resulting in a loss in efficacy.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Imatinib.
GenisteinThe serum concentration of Imatinib can be increased when it is combined with Genistein.
GlipizideThe metabolism of Glipizide can be decreased when combined with Imatinib.
GlyburideThe metabolism of Glyburide can be decreased when combined with Imatinib.
GlyburideThe serum concentration of Imatinib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Imatinib can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Imatinib can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be decreased when combined with Imatinib.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Imatinib.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Imatinib.
GrepafloxacinThe serum concentration of Imatinib can be increased when it is combined with Grepafloxacin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Imatinib.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Imatinib.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Imatinib.
HaloperidolThe serum concentration of Imatinib can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Imatinib.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Imatinib.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Imatinib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Imatinib.
HydrocortisoneThe serum concentration of Imatinib can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Imatinib.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Imatinib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Imatinib.
IbuprofenThe serum concentration of Imatinib can be decreased when it is combined with Ibuprofen.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Imatinib.
IdelalisibThe serum concentration of Imatinib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Imatinib resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imatinib can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Imatinib.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Imatinib.
IndapamideThe metabolism of Indapamide can be decreased when combined with Imatinib.
IndinavirThe serum concentration of Imatinib can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Imatinib.
IndomethacinThe serum concentration of Imatinib can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Imatinib.
IrbesartanThe metabolism of Imatinib can be decreased when combined with Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Imatinib.
IsavuconazoniumThe serum concentration of Imatinib can be increased when it is combined with Isavuconazonium.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Imatinib.
IsoniazidThe metabolism of Imatinib can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Imatinib.
IsradipineThe serum concentration of Imatinib can be increased when it is combined with Isradipine.
IsradipineThe metabolism of Isradipine can be decreased when combined with Imatinib.
ItraconazoleThe serum concentration of Imatinib can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Imatinib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Imatinib.
IvacaftorThe serum concentration of Imatinib can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Imatinib.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Imatinib.
IvermectinThe serum concentration of Imatinib can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Imatinib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Imatinib.
KetamineThe metabolism of Ketamine can be decreased when combined with Imatinib.
KetamineThe serum concentration of Imatinib can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Imatinib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Imatinib.
KetoconazoleThe serum concentration of Imatinib can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Imatinib.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Imatinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Imatinib.
LansoprazoleLansoprazole may increase the dermatologic adverse activities of Imatinib.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Imatinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Imatinib.
LapatinibThe serum concentration of Imatinib can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Imatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Imatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Imatinib is combined with Leflunomide.
LeflunomideThe metabolism of Imatinib can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Imatinib.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Imatinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Imatinib.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Imatinib.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Imatinib.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Imatinib.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Imatinib.
LevofloxacinThe serum concentration of Imatinib can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Imatinib.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Imatinib.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Imatinib.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Imatinib.
LevothyroxineThe serum concentration of Imatinib can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Imatinib.
LidocaineThe serum concentration of Imatinib can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Imatinib.
LiothyronineThe serum concentration of Imatinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Imatinib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Imatinib can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Imatinib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Imatinib.
LoperamideThe metabolism of Loperamide can be decreased when combined with Imatinib.
LoperamideThe serum concentration of Imatinib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Imatinib can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Imatinib.
LoratadineThe metabolism of Loratadine can be decreased when combined with Imatinib.
LoratadineThe serum concentration of Imatinib can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Imatinib.
LosartanThe metabolism of Losartan can be decreased when combined with Imatinib.
LosartanThe serum concentration of Imatinib can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Imatinib can be increased when it is combined with Lovastatin.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Imatinib.
LuliconazoleThe serum concentration of Imatinib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Imatinib can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Imatinib.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Imatinib.
MacitentanThe metabolism of Macitentan can be decreased when combined with Imatinib.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Imatinib.
MaprotilineThe serum concentration of Imatinib can be increased when it is combined with Maprotiline.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Imatinib.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Imatinib.
MebendazoleThe serum concentration of Imatinib can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Imatinib.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Imatinib.
MefloquineThe serum concentration of Imatinib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Imatinib can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Imatinib.
MeprobamateThe serum concentration of Imatinib can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Imatinib.
MethadoneThe metabolism of Methadone can be decreased when combined with Imatinib.
MethadoneThe serum concentration of Imatinib can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Imatinib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Imatinib.
MethotrimeprazineThe metabolism of Imatinib can be decreased when combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Imatinib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Imatinib.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Imatinib.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Imatinib.
MetoprololThe serum concentration of Imatinib can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Imatinib.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Imatinib.
MianserinThe metabolism of Mianserin can be decreased when combined with Imatinib.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Imatinib.
MibefradilThe serum concentration of Imatinib can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Imatinib.
MiconazoleThe serum concentration of Imatinib can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Imatinib.
MidazolamThe serum concentration of Imatinib can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Imatinib can be increased when it is combined with Mifepristone.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Imatinib.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Imatinib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Imatinib.
MitomycinThe serum concentration of Imatinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Imatinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Imatinib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Imatinib.
MoclobemideThe metabolism of Imatinib can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Imatinib can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Imatinib.
MontelukastThe metabolism of Montelukast can be decreased when combined with Imatinib.
MorphineThe metabolism of Morphine can be decreased when combined with Imatinib.
MorphineThe serum concentration of Imatinib can be increased when it is combined with Morphine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Imatinib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Imatinib.
NafcillinThe serum concentration of Imatinib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Imatinib.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Imatinib.
NaltrexoneThe serum concentration of Imatinib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Imatinib can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Imatinib.
NefazodoneThe serum concentration of Imatinib can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Imatinib.
NelfinavirThe serum concentration of Imatinib can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Imatinib.
NeostigmineThe serum concentration of Imatinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Imatinib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Imatinib can be increased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Imatinib.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Imatinib.
NicardipineThe serum concentration of Imatinib can be increased when it is combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Imatinib.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Imatinib.
NifedipineThe serum concentration of Imatinib can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Imatinib can be increased when it is combined with Nilotinib.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Imatinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Imatinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Imatinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Imatinib.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Imatinib.
NisoldipineThe serum concentration of Imatinib can be increased when it is combined with Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Imatinib.
NitrazepamThe serum concentration of Imatinib can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Imatinib.
NitrendipineThe serum concentration of Imatinib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Imatinib.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Imatinib.
NorethisteroneThe serum concentration of Imatinib can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Imatinib.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Imatinib.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Imatinib.
OlaparibThe serum concentration of Imatinib can be increased when it is combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Imatinib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Imatinib.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Imatinib.
OmeprazoleThe serum concentration of Imatinib can be increased when it is combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Imatinib.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Imatinib.
OsimertinibThe serum concentration of Imatinib can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Imatinib.
OuabainOuabain may decrease the cardiotoxic activities of Imatinib.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Imatinib.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Imatinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Imatinib.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Imatinib.
P-NitrophenolThe serum concentration of Imatinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Imatinib.
PaclitaxelThe serum concentration of Imatinib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Imatinib can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Imatinib.
Palmitic AcidThe serum concentration of Imatinib can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Imatinib.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Imatinib.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Imatinib.
PantoprazoleThe serum concentration of Imatinib can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Imatinib.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Imatinib.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Imatinib.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Imatinib.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Imatinib.
ParoxetineThe serum concentration of Imatinib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Imatinib.
Peginterferon alfa-2bThe serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Imatinib.
PentobarbitalThe serum concentration of Imatinib can be decreased when it is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Imatinib.
PergolideThe metabolism of Pergolide can be decreased when combined with Imatinib.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Imatinib.
PerindoprilThe serum concentration of Imatinib can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Imatinib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Imatinib.
PethidineThe metabolism of Pethidine can be decreased when combined with Imatinib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Imatinib.
PhenobarbitalThe serum concentration of Imatinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Imatinib.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Imatinib.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Imatinib.
PhenytoinThe serum concentration of Imatinib can be decreased when it is combined with Phenytoin.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Imatinib.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Imatinib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Imatinib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Imatinib.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Imatinib.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Imatinib.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Imatinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Imatinib.
Platelet Activating FactorThe serum concentration of Imatinib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Imatinib.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Imatinib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Imatinib.
PonatinibThe serum concentration of Imatinib can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Imatinib can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Imatinib.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Imatinib.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Imatinib.
PravastatinThe serum concentration of Imatinib can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Imatinib.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Imatinib.
PrazosinThe serum concentration of Imatinib can be increased when it is combined with Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Imatinib.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Imatinib.
PrednisoneThe serum concentration of Imatinib can be increased when it is combined with Prednisone.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Imatinib.
PrimidoneThe serum concentration of Imatinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Imatinib can be increased when it is combined with Probenecid.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Imatinib.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Imatinib.
ProgesteroneThe serum concentration of Imatinib can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Imatinib.
PromazineThe metabolism of Promazine can be decreased when combined with Imatinib.
PromethazineThe serum concentration of Imatinib can be increased when it is combined with Promethazine.
PropacetamolPropacetamol may increase the hepatotoxic activities of Imatinib.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Imatinib.
PropofolThe metabolism of Propofol can be decreased when combined with Imatinib.
PropranololThe metabolism of Propranolol can be decreased when combined with Imatinib.
PropranololThe serum concentration of Imatinib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Imatinib can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Imatinib.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Imatinib.
PyrimethamineThe metabolism of Imatinib can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Imatinib.
QuercetinThe serum concentration of Imatinib can be increased when it is combined with Quercetin.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Imatinib.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Imatinib.
QuinacrineThe serum concentration of Imatinib can be increased when it is combined with Quinacrine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Imatinib.
QuinidineThe serum concentration of Imatinib can be increased when it is combined with Quinidine.
QuinineThe metabolism of Quinine can be decreased when combined with Imatinib.
QuinineThe serum concentration of Imatinib can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Imatinib.
Rabies vaccineThe risk or severity of adverse effects can be increased when Imatinib is combined with Rabies vaccine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Imatinib.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Imatinib.
RanitidineThe serum concentration of Imatinib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Imatinib.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Imatinib.
ReboxetineThe serum concentration of Imatinib can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Imatinib.
RegorafenibThe serum concentration of Imatinib can be increased when it is combined with Regorafenib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Imatinib.
ReserpineThe serum concentration of Imatinib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Imatinib.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Imatinib.
RifabutinThe serum concentration of Imatinib can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Imatinib.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Imatinib.
RifampicinThe serum concentration of Imatinib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Imatinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Imatinib.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Imatinib.
RilpivirineThe serum concentration of Imatinib can be increased when it is combined with Rilpivirine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Imatinib.
RiociguatThe metabolism of Riociguat can be decreased when combined with Imatinib.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Imatinib.
RitonavirThe serum concentration of Imatinib can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Imatinib.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Imatinib.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Imatinib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Imatinib.
RolapitantThe serum concentration of Imatinib can be increased when it is combined with Rolapitant.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Imatinib.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Imatinib.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Imatinib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Imatinib.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Imatinib.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Imatinib.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Imatinib.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Imatinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Imatinib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Imatinib.
SaquinavirThe serum concentration of Imatinib can be increased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Imatinib.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Imatinib.
ScopolamineThe serum concentration of Imatinib can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Imatinib can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Imatinib.
SelegilineThe serum concentration of Imatinib can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Imatinib.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Imatinib.
SertindoleThe metabolism of Sertindole can be decreased when combined with Imatinib.
SertralineThe metabolism of Sertraline can be decreased when combined with Imatinib.
SertralineThe serum concentration of Imatinib can be increased when it is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Imatinib.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Imatinib.
SildenafilThe serum concentration of Imatinib can be increased when it is combined with Sildenafil.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Imatinib.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Imatinib.
SiltuximabThe serum concentration of Imatinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Imatinib can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Imatinib.
SimvastatinThe serum concentration of Imatinib can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imatinib.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Imatinib.
SirolimusThe serum concentration of Imatinib can be decreased when it is combined with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Imatinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Imatinib.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Imatinib.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Imatinib.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Imatinib.
SorafenibThe serum concentration of Imatinib can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Imatinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Imatinib.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Imatinib.
SpironolactoneThe serum concentration of Imatinib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Imatinib can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Imatinib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Imatinib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Imatinib can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Imatinib.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Imatinib.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Imatinib.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Imatinib.
SulfinpyrazoneThe serum concentration of Imatinib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe serum concentration of Imatinib can be increased when it is combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.
SumatriptanThe serum concentration of Imatinib can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Imatinib.
SunitinibThe serum concentration of Imatinib can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Imatinib.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Imatinib.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Imatinib.
TacrineThe serum concentration of Imatinib can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Imatinib.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Imatinib.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Imatinib.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Imatinib.
TamoxifenThe serum concentration of Imatinib can be decreased when it is combined with Tamoxifen.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Imatinib.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Imatinib.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Imatinib.
Taurocholic AcidThe serum concentration of Imatinib can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Imatinib.
TelaprevirThe serum concentration of Imatinib can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Imatinib.
TelithromycinThe serum concentration of Imatinib can be increased when it is combined with Telithromycin.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Imatinib.
TelmisartanThe serum concentration of Imatinib can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Imatinib.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Imatinib.
TemsirolimusThe serum concentration of Imatinib can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Imatinib.
TenofovirThe metabolism of Imatinib can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Imatinib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Imatinib.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Imatinib.
TerfenadineThe serum concentration of Imatinib can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Imatinib.
TesmilifeneThe serum concentration of Imatinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Imatinib.
TestosteroneThe serum concentration of Imatinib can be increased when it is combined with Testosterone.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Imatinib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Imatinib.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Imatinib.
ThioridazineThe metabolism of Imatinib can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Imatinib.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Imatinib.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Imatinib.
TicagrelorThe serum concentration of Imatinib can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Imatinib can be increased when it is combined with Ticlopidine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Imatinib.
TimololThe serum concentration of Timolol can be increased when it is combined with Imatinib.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Imatinib.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Imatinib.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Imatinib.
TocilizumabThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.
TofacitinibImatinib may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Imatinib can be decreased when combined with Tolbutamide.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Imatinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Imatinib.
TopiramateThe metabolism of Imatinib can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Imatinib.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Imatinib.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Imatinib.
TramadolThe metabolism of Tramadol can be decreased when combined with Imatinib.
TranylcypromineThe metabolism of Imatinib can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Imatinib.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Imatinib.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Imatinib.
TrazodoneThe serum concentration of Imatinib can be decreased when it is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Imatinib.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Imatinib.
TriazolamThe metabolism of Triazolam can be decreased when combined with Imatinib.
TrifluoperazineThe serum concentration of Imatinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Imatinib can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Imatinib.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Imatinib.
TrimethoprimThe serum concentration of Imatinib can be decreased when it is combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Imatinib.
TrimipramineThe serum concentration of Imatinib can be increased when it is combined with Trimipramine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Imatinib.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Imatinib.
TroleandomycinThe serum concentration of Imatinib can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Imatinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Imatinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Imatinib.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Imatinib.
Valproic AcidThe metabolism of Imatinib can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Imatinib can be decreased when combined with Valsartan.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Imatinib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Imatinib.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Imatinib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Imatinib.
VemurafenibThe serum concentration of Imatinib can be increased when it is combined with Vemurafenib.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Imatinib.
VenlafaxineThe serum concentration of Imatinib can be increased when it is combined with Venlafaxine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Imatinib.
VerapamilThe serum concentration of Imatinib can be increased when it is combined with Verapamil.
VerapamilThe metabolism of Verapamil can be decreased when combined with Imatinib.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Imatinib.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Imatinib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Imatinib.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Imatinib.
VinblastineThe serum concentration of Imatinib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Imatinib.
VincristineThe serum concentration of Imatinib can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Imatinib.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Imatinib.
VinorelbineThe serum concentration of Imatinib can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Imatinib.
VoriconazoleThe serum concentration of Imatinib can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Imatinib.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Imatinib.
WarfarinThe metabolism of Warfarin can be decreased when combined with Imatinib.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Imatinib.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Imatinib.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Imatinib.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Imatinib.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Imatinib.
ZileutonThe metabolism of Zileuton can be decreased when combined with Imatinib.
ZimelidineThe serum concentration of Imatinib can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Imatinib can be increased when it is combined with Ziprasidone.
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Imatinib.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Imatinib.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Imatinib.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Imatinib.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Imatinib.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.
Food Interactions
  • Take with food to reduce the incidence of gastric irritation. Follow with a large glass of water. A lipid rich meal will slightly reduce and delay absorption. Avoid grapefruit and grapefruit juice throughout treatment, grapefruit can significantly increase serum levels of this product.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Not Available
Gene Name:
BCR/ABL fusion
Uniprot ID:
A9UF02
Molecular Weight:
179321.835 Da
References
  1. Nadal E, Olavarria E: Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. Int J Clin Pract. 2004 May;58(5):511-6. [PubMed:15206509 ]
  2. Waller CF: Imatinib mesylate. Recent Results Cancer Res. 2010;184:3-20. doi: 10.1007/978-3-642-01222-8_1. [PubMed:20072827 ]
  3. Croom KF, Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63(5):513-22; discussion 523-4. [PubMed:12600228 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistmultitarget
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Lee JL, Kim JY, Ryu MH, Kang HJ, Chang HM, Kim TW, Lee H, Park JH, Kim HC, Kim JS, Kang YK: Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. Dig Dis Sci. 2006 Jun;51(6):1043-6. [PubMed:16865565 ]
  2. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov;16(11):1811-6. Epub 2005 Aug 8. [PubMed:16087693 ]
  3. Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Wozniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W: Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26. [PubMed:17458563 ]
  4. De Giorgi U: KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors. J Clin Oncol. 2007 Mar 20;25(9):1146-7; author reply 1147-8. [PubMed:17369583 ]
  5. Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC: A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007 Jul 15;110(2):309-17. [PubMed:17559139 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
RET
Uniprot ID:
O43519
Molecular Weight:
2129.3 Da
References
  1. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM: Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006 Jun;139(6):806-14. [PubMed:16782438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 ...
Gene Name:
NTRK1
Uniprot ID:
P04629
Molecular Weight:
87496.465 Da
References
  1. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital. 2005 Jan-Feb;57(1):127-33. [PubMed:15832750 ]
  2. Kovacs M, Nagy P, Pak G, Feher J: [Gastrointestinal stromal tumors (GISTs): clinical and pathological features]. Orv Hetil. 2005 Jun 26;146(26):1375-81. [PubMed:16052979 ]
  3. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM: Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006 Jun;139(6):806-14. [PubMed:16782438 ]
  4. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9. Epub 2007 Jun 19. [PubMed:17579194 ]
  5. Delbaldo C: [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]. Therapie. 2007 Mar-Apr;62(2):87-90. Epub 2007 Jun 21. [PubMed:17582306 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in inn...
Gene Name:
CSF1R
Uniprot ID:
P07333
Molecular Weight:
107982.955 Da
References
  1. Dewar AL, Zannettino AC, Hughes TP, Lyons AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005 Jul;4(7):851-3. Epub 2005 Jul 28. [PubMed:15917650 ]
  2. Taylor JR, Brownlow N, Domin J, Dibb NJ: FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006 Jan 5;25(1):147-51. [PubMed:16170366 ]
  3. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC: Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006 Jun 1;107(11):4334-7. Epub 2006 Jan 31. [PubMed:16449525 ]
  4. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab. 2006;24(4):274-82. [PubMed:16816921 ]
  5. El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S: Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol. 2006 Dec 3;551(1-3):27-33. Epub 2006 Sep 16. [PubMed:17049513 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. Yi ES, Strong CR, Piao Z, Perucho M, Weidner N: Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity. Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):157-61. [PubMed:15894928 ]
  2. Borbenyi Z: [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. [PubMed:15921304 ]
  3. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. [PubMed:15928335 ]
  4. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS: Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005 Jul;7(4):293-9. [PubMed:15946589 ]
  5. Tefferi A: Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52-60. [PubMed:15995325 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular mat...
Gene Name:
DDR1
Uniprot ID:
Q08345
Molecular Weight:
101126.72 Da
References
  1. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005 Oct 15;106(8):2865-70. Epub 2005 Jun 21. [PubMed:15972446 ]
  2. Xu L, Tong R, Cochran DM, Jain RK: Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005 Jul 1;65(13):5711-9. [PubMed:15994946 ]
  3. Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J: Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol. 2006 Jan;44(1):167-75. Epub 2005 Jul 12. [PubMed:16168515 ]
  4. Jubert C, Geoerger B, Grill J, Hartmann O, Vassal G: [Targeted therapies in pediatric oncology: a new therapeutic approach?]. Arch Pediatr. 2006 Feb;13(2):189-94. Epub 2005 Nov 17. [PubMed:16298518 ]
  5. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B: Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006 Jan;11(1):9-20. [PubMed:16401709 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Hoerth E, Kodym R: Involvment of c-Abl in the radiation-induced inhibition of myoblast differentiation. Int J Radiat Biol. 2004 Oct;80(10):729-36. [PubMed:15799618 ]
  2. Dewar AL, Zannettino AC, Hughes TP, Lyons AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005 Jul;4(7):851-3. Epub 2005 Jul 28. [PubMed:15917650 ]
  3. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Larrayoz MJ, Lahortiga I, Andreu EJ, Marquez J, Beltran de Heredia JM, Odero MD, Prosper F, Calasanz MJ: Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. Cancer Genet Cytogenet. 2005 Jul 1;160(1):22-6. [PubMed:15949566 ]
  4. Brueggemeier SB, Wu D, Kron SJ, Palecek SP: Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules. 2005 Sep-Oct;6(5):2765-75. [PubMed:16153117 ]
  5. Haberler C, Gelpi E, Marosi C, Rossler K, Birner P, Budka H, Hainfellner JA: Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol. 2006 Jan;76(2):105-9. [PubMed:16205964 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L: Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res. 2005 Mar 1;65(5):1897-903. [PubMed:15753388 ]
  2. Jones RL, Judson IR: The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar;4(2):183-91. [PubMed:15794712 ]
  3. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. [PubMed:15803362 ]
  4. Johnson FM, Saigal B, Donato NJ: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol. 2005 Nov;205(2):218-27. [PubMed:15887238 ]
  5. Chen J, Rocken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett. 2006 Feb 28;233(2):328-37. [PubMed:15893416 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702 ]
  2. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL: Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11. [PubMed:20147974 ]
  3. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstrom CA, Artursson P: Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42. doi: 10.1021/jm8003152. Epub 2008 Sep 13. [PubMed:18788725 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702 ]
  2. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  3. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485 ]
  4. Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004 Dec 1;104(12):3739-45. Epub 2004 Aug 17. [PubMed:15315971 ]
  5. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  6. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31. [PubMed:18669873 ]
  7. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82. [PubMed:15805252 ]
  8. Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters]. Gan To Kagaku Ryoho. 2005 May;32(5):585-92. [PubMed:15918555 ]
  9. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9. [PubMed:15970668 ]
  10. Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M: Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet. 2005 Oct 1;162(1):57-62. [PubMed:16157201 ]
  11. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201. [PubMed:16890580 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Tanihara Y, Masuda S, Katsura T, Inui K: Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol. 2009 Nov 1;78(9):1263-71. doi: 10.1016/j.bcp.2009.06.014. Epub 2009 Jun 18. [PubMed:19540211 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004 Apr 1;64(7):2333-7. [PubMed:15059881 ]
  2. An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. [PubMed:19708828 ]
  3. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702 ]
  4. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  5. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2. Epub 2004 Jul 13. [PubMed:15251980 ]
  6. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  7. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82. [PubMed:15805252 ]
  8. Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters]. Gan To Kagaku Ryoho. 2005 May;32(5):585-92. [PubMed:15918555 ]
  9. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9. [PubMed:15970668 ]
  10. Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y: Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21. [PubMed:16303243 ]
  11. Nakanishi T, Shiozawa K, Hassel BA, Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 2006 Jul 15;108(2):678-84. Epub 2006 Mar 16. [PubMed:16543472 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Plays an important role in the formation of pulmonary surfactant, probably by transporting lipids such as cholesterol.
Gene Name:
ABCA3
Uniprot ID:
Q99758
Molecular Weight:
191360.235 Da
References
  1. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG: ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica. 2009 Nov;94(11):1528-36. doi: 10.3324/haematol.2009.008631. [PubMed:19880777 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31